DOCSLIB.ORG

INFORMATION to USERS the Most Advanced

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
INFORMATION to USERS the Most Advanced INFORMATION TO USERS The most advanced technology has been used to photo­ graph and reproduce this manuscript from the microfilm master. UMI films the original text directly from the copy submitted. Thus, some dissertation copies are in typewriter face, while others may be from a computer printer. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyrighted material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are re­ produced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each oversize page is available as one exposure on a standard 35 mm slide or as a 17" x 23" black and white photographic print for an additional charge. Photographs included in the original manuscript have been reproduced xerographically in this copy. 35 mm slides or 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. Accessing the World’sUMI Information since 1938 300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA Order Number 8804083 Drug stabilization through molecular modification: Hydrolysis kinetics of ampicillin prodrugs and nucleoside analogs Nguyen, Ngoc-Anh Thi, Ph.D. The Ohio State University, 1987 UMI 300 N. Zccb Rd. Ann Arbor, MI 48106 DRUG STABILIZATION THROUGH MOLECULAR MODIFICATION: HYDROLYSIS KINETICS OF AMPICILLIN PRODRUGS AND NUCLEOSIDE ANALOGS DISSERTATION Presented In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Ngoc-Anh T. Nguyen, B.S. >!t >|c ilc >!< )|i The Ohio State University 1907 Dissertation Committee: Approved by Robert E. Notari, Ph.D. Theodore D. Sokoloski, Ph.D. Alfred E. Staubus, Ph.D. A dviser College of Pharmacy DEDICATION To Mom and Dad Cong cha nhx? nul Thai S<3n, Nghia^ me nhu 9 nu<3ca * trong nguon chay ra.9 ' MotA longv th<3 “me kinh7 cha • * Cho tron chvl hieu moi la clao con. 9 - ii - ACKNOWLEDGEMENTS I wish to sincerely thank my adviser, Professor Robert E. Notari, for his patience, invaluable advice and thoughtful guidance. His insights and generosity of time were instrumental in the completion of this project. I have learned much from the Pharmaceutics faculty, staff, and fel­ low graduate students and have appreciated their kindness and friend­ ship. In particular, I thank Dr. Louis Malspeis for the loan of equip­ ment in time of crisis, for helpful discussions, and for his generosity and support. I like to particularly thank Mehdl Mansoorl for his encouragement and support through my undergraduate and graduate studies. I especially wish to thank Mom and Dad for their love and support. The financial support from the College of Pharmacy is appreciated. I would also like to thank: Dr. J.L. DeYoung and the Wyeth Co. for Ampicillin Dr. J.B. D'Silva and Pfizer Inc. for Bacamplcillin Dr. Tokuji Suzuki, University of Chiba, Dr. Shigeo Kawamura and Yamanouchi Pharmaceuticals, Japan, for Talampicillin. - H i - VITA May 15, 1959 ............................................Born - Trung Hieu, Vinh Long, Viet Nam. 1982 ................................................................B . S ., C hem istry The University of Michigan Ann Arbor, Michigan 1982-1987 .....................................................Graduate Teaching Associate The Division of Pharmaceutics and Pharmaceutical Chemistry College of Pharmacy The Ohio State University Columbus, Ohio FIELD OF STUDY Major Field: Pharmaceutics and Pharmaceutical Chemistry TABLE OF CONTENTS PAGE DEDICATION ................................................................................................................ ii ACKNOWLEDGEMENTS ................................................................................................iii VITA ................................................................................................................................. iv LIST OF TABLES ........................................................................................................... vii LIST OF FIGURES ........................................................................................................ ix CHAPTER 1. DEVELOPMENT OF REVERSE-PHASE HPLC ASSAYS FOR AMPICILLIN AND ITS PRODRUGS.............................................. 2 SUMMARY ................................................................................................... 3 INTRODUCTION ......................................................................................... 4 EXPERIMENTAL ......................................................................................... 7 RESULTS AND DISCUSSION ............................................................... 8 REFERENCES ........................................................................................... 16 2. KINETICS OF PRODRUG STABILITY: BACAMPICILLIN AND TALAMPICILLIN ......................................................................26 SUMMARY....................................................................................................27 INTRODUCTION .......................................................................................28 EXPERIMENTAL .......................................................................................38 RESULTS ....................................................................................................40 DISCUSSION ........................................................................................... 48 REFERENCES ........................................................................................... 58 - v - 3. KINETIC REQUIREMENTS FOR OPTIMIZATION OF PRODRUG UTILIZATION TIME ................................................ 93 SUMMARY....................................................................................................94 INTRODUCTION .......................................................................................95 EXPERIMENTAL .....................................................................................106 RESULTS AND DISCUSSION .............................................. 109 REFERENCES .........................................................................................125 4. SUBSTITUENT EFFECTS ON DEGRADATION RATES AND PATHWAYS OF CYTOSINE NUCLEO SIDES.........................139 SUMMARY..................................................................................................140 INTRODUCTION .....................................................................................141 EXPERIMENTAL .....................................................................................145 RESULTS ..................................................................................................149 DISCUSSION ......................................................................................... 157 REFERENCES ......................................................................................... 167 - vi - LIST OF TABLES TABLE PAGE 1.1 Retention Times of Ampicillin With and Without Tetrabutylammonium H ydroxide ............................................... 19 1.2 Retention Times of Ampicillin and Bacampicillin with Heptane sulfonate S odium ..........................................................................20 1.3 Isocratic Assays of Ampicillin and its P rodrugs ........................... 21 2.1 Summary of Rate Constants for Bacampicillin ................................61 2.2 Summary of Rate Constants for Ampicillin ........................................ 63 2.3 Summary of Rate Constants for Ampicillin and Bacampicillin in the Absence of B uffers ............................................65 2.4 Summary of Rate Constants for Talamplcillin . ........................ 6 6 2.5 HPLC Assays for Ampicillin, Bacampicillin and Talampicillin ....................................................................................................6 8 2.6 Summary of Catalytic Constants and Energetics .............................69 2.7 Catalytic Constants Defining Conversion and Degradation ................................................... 70 2.8 General Acid and General Base Catalytic Constants . 71 2.9 Utilization Time for Ampicillin, Bacampicillin and Talampicillin ....................................................................................................72 4.1 Rate Constants for 5-Methyldeoxycytidine Degradation . 169 4.2 Rate Constants for Substituted and Unsubstituted Cytosine N ucleosides .................................................................................170 4.3 HPLC Characteristics of Nucleosides and B a se s ...................... 171 4.4 Total Recovery of 5-Methyldeoxycytidine at pH 4.58 . 172 4.5 Total Recovery of 6 -Methylcytidine at pH 3.63 173 - vii - 4.G Total Recovery of Arablnosylcytosine at pH 1.14 .......................... 174 4.7 Recovery of G-Methylarabinosylcytosine at pH 1.14 . 175 - v i i i - LIST OF FIGURES HPLC chromatograms of bacampicillin (1) and ampicillin (3) in a ...................................................................... 22 HPLC chromatograms of ampicillin in the absence (A ,B ) ................................................................................................ 23 HPLC chromatograms of bacampicillin (A) and ampicillin (B ) ....................................................................................
Load more

Recommended publications
  • A New Trigger of Morbilliform Eruption in the Setting of Atypical Infectious
    A New Trigger of Morbilliform Eruption in the Setting of Atypical Infectious Mononucleosis Roxanne Rajaii, DO,* Megan Furniss, DO,** John Pui, MD,*** Brett Bender, DO**** *Dermatology Resident, PGY2, Beaumont Hospital - Farmington Hills, Farmington Hills, MI **Dermatology Resident, PGY4, Beaumont Hospital - Farmington Hills, Farmington Hills, MI ***Dermatopathologist, Beaumont Hospital - Farmington Hills, Farmington Hills, MI ****Dermatologist, Beaumont Hospital - Farmington Hills, Farmington Hills, MI Disclosures: None Correspondence: Roxanne Rajaii, DO; [email protected] Abstract Morbilliform eruptions, also commonly referred to as exanthematous or maculopapular drug eruptions, are the most common type of hypersensitivity reaction and can vary in etiology. Antibiotics are a common trigger, most notably amoxicillin or ampicillin in the setting of a concomitant and acute Epstein-Barr virus (EBV) infection. However, other antibiotics have been identified to cause a similar reaction in the setting of EBV. Cephalexin, a commonly used cephalosporin, is the only antibiotic in its class that has been implicated in causing such a phenomenon. We present a unique case of a morbilliform eruption in the setting of EBV secondary to the use of cefepime, further outlining the importance of conservative antibiotic use and awareness of such a reaction in this specific patient population, not only with penicillins but also with a wider spectrum of antibiotics. Introduction acquired pyelonephritis, as she had been admitted Work-up included the following laboratory tests: Epstein-Barr virus (EBV) infects more than a month prior to that for status asthmaticus. complete blood count, complete metabolic panel, 98% of the world’s adult population and is the Four days later, she presented with an urticarial anti-nuclear antibody, creatinine phosphate kinase, most common cause of infectious mononucleosis morbilliform rash.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]
  • Reflection Paper on the Use of Aminopenicillins and Their Beta
    1 13 September 2018 2 EMA/CVMP/AWP/842786/2015 3 Committee for Medicinal Products for Veterinary Use (CVMP) 4 Reflection paper on the use of aminopenicillins and their 5 beta-lactamase inhibitor combinations in animals in the 6 European Union: development of resistance and impact 7 on human and animal health 8 Draft Draft agreed by Antimicrobials Working Party (AWP) 9 July 2018 Adopted by CVMP for release for consultation 13 September 2018 Start of public consultation 21 September 2018 End of consultation (deadline for comments) 21 December 2018 9 Comments should be provided using this template. The completed comments form should be sent to [email protected] 10 Keywords aminopenicillins, antimicrobial resistance 11 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 12 13 Table of contents 14 Executive summary ..................................................................................... 4 15 CVMP Recommendations for action ............................................................. 6 16 1. Background ............................................................................................. 7 17 2. General drug characteristics .................................................................... 8 18 2.1. Structure and mechanism of action ......................................................................
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Antibacterial Prodrugs to Overcome Bacterial Resistance
    molecules Review Antibacterial Prodrugs to Overcome Bacterial Resistance Buthaina Jubeh , Zeinab Breijyeh and Rafik Karaman * Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem P.O. Box 20002, Palestine; [email protected] (B.J.); [email protected] (Z.B.) * Correspondence: [email protected] or rkaraman@staff.alquds.edu Academic Editor: Helen Osborn Received: 10 March 2020; Accepted: 26 March 2020; Published: 28 March 2020 Abstract: Bacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and effort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological effects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria. Keywords: prodrugs; biotransformation; targeting; β-lactam antibiotics; β-lactamases; pathogens; resistance 1. Introduction Nowadays, the issue of pathogens resistant to drugs and the urgent need for new compounds that are capable of eradicating these pathogens are well known and understood.
    [Show full text]
  • Antimicrobial Composition
    Europa,schesP_ MM M II M MM 1 1 M Ml MM M Ml J European Patent Office .ha no © Publication number: 0 384 41 OBI Office europeen, desJ brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 17.05.95 © Int. CI.6: A61 K 31/545, A61 K 31/43, //(A61K31/545,31:43) © Application number: 90103266.4 @ Date of filing: 20.02.90 The file contains technical information submitted after the application was filed and not included in this specification © Antimicrobial composition. ® Priority: 21.02.89 JP 41286/89 9-1, Kamimutsuna 3-chome 14.04.89 JP 94460/89 Okazaki-shi, Aichi (JP) @ Date of publication of application: Inventor: Sanada, Mlnoru, c/o BANYU PHARM. 29.08.90 Bulletin 90/35 CO., LTD. OKAZAKI RES. LABORATORY, © Publication of the grant of the patent: 9-1, Kamimutsuna 3-chome 17.05.95 Bulletin 95/20 Okazaki-shi, Aichi (JP) © Designated Contracting States: Inventor: Nakagawa, Susumu, c/o BANYU CH DE FR GB IT LI NL PHARM. CO., LTD. OKAZAKI RES. LABORATORY, © References cited: 9-1, Kamimutsuna 3-chome EP-A- 0 248 361 Okazaki-shi, Aichi (JP) UNLISTED DRUGS, vol. 37, no. 2, February Inventor: Tanaka, Nobuo, c/o BANYU PHARM. 1985, Chatham, New Jersey, US; "Zienam CO., LTD. 250". 2-3, Nihonbashi Honcho 2-chome Chuo-ku, © Proprietor: BANYU PHARMACEUTICAL CO., Tokyo (JP) LTD. Inventor: Inoue, Matsuhisa 2-3, Nihonbashi Honcho 2-chome 3076-3, Oaza-Tokisawa 00 Chuo-ku, Tokyo (JP) Fujlmi-mura, Seta-gun, @ Inventor: Matsuda, Kouji, c/o BANYU PHARM. Gunma (JP) CO., LTD.
    [Show full text]
  • Talampicillin: a New Derivative of Ampicillin Br Med J: First Published As 10.1136/Bmj.1.6022.1378 on 5 June 1976
    1378 BRITISH MEDICAL JOURNAL 5 JUNE 1976 Talampicillin: a new derivative of ampicillin Br Med J: first published as 10.1136/bmj.1.6022.1378 on 5 June 1976. Downloaded from D A LEIGH, D S REEVES, KATE SIMMONS, A L THOMAS, P J WILKINSON British Medical3Journal, 1976, 1, 1378-1380 ampicillin either after an overnight fast, or within 45 minutes of a standard breakfast. Serum levels were measured one, two, four, six, and eight hours after the dose and all urine was collected for two Summary consecutive six-hour periods and the subsequent 12-hour period. Thirteen patients treated with 750 mg of talampicillin twice daily Talampicillin is a thiazolide carboxylic ester of ampicillin had serum concentrations monitored after their first dose, which was and is hydrolysed in the intestinal mucosa to release variably related to their last meal. Most patients in the clinical trial free ampicillin. The mean peak serum concentration (see below) had urinary concentrations and total recoveries measured ofampicillin occurred one hour after a dose of talampicil- for the first 48 hours of treatment. In all studies ampicillin was lin and was about twice that attained by an equivalent assayed by a plate diffusion method using the Oxford staphylococcus (NCTC 6571) (at High Wycombe) or Bacillus subtilis (NCTC 6633) dose of ampicillin. The presence of food in the stomach (at Bristol) as the indicator strain. reduced and delayed the peak blood levels but did not affect the total amount of antibiotic absorbed or the urinary recovery. Talampicillin had less effect on the faecal flora in volunteers than ampicillin, and no over- FAECAL FLORA STUDY growth with Candida spp or Staphylococcus aureus was Ten healthy volunteers took 250 mg of talampicillin four times a seen.
    [Show full text]
  • Role of Beta-Lactam Antibiotics in Periodontal Disease Jyoti Kasana1, Nisha Singh2, Priyanka Choudhary3, Bhupender Bhati4, Harpreet Grewal5
    IJPCDR REVIEW ARTICLE Role of Beta-Lactam Antibiotics in Periodontal Disease Jyoti Kasana1, Nisha Singh2, Priyanka Choudhary3, Bhupender Bhati4, Harpreet Grewal5 ABSTRACT Penicillianse-resistant penicillins Beta-lactam antibiotics are one of the most commonly • Acid labile – methicillin, nafcillin, cloxacillin, and prescribed drug classes with numerous clinical indications. dicloxacillin From a biochemical point of view, these drugs have a common • Acid resistant – flucloxacillin. feature, which is the 3-carbon and 1-nitrogen ring (beta-lactam ring) that is highly reactive. Penicillins effective against Gram-positive and some Keywords: Beta-lactam, Loading dose, Penicillin. Gram-negative organisms How to cite this article: Kasana J, Singh N, Choudhary P, • Ampicillin Bhati B, Grewal H. Role of Beta-Lactam Antibiotics in Periodontal Disease. Int J Prev Clin Dent Res 2018;5(1):153-154. • Amoxicillin • Talampicillin. Source of support: Nil Conflicts of interest: None Extended-spectrum penicillins • Carboxypenicillins – carbenicillin and ticarcillin INTRODUCTION • Ureidopenicillins – piperacillin and mezlocillin The discovery of Penicillin by Sir Alexander Fleming in • Amidino penicillins – mecillinam and pivmecillinam. 1928 remains part of medicine folklore • First antibiotic used in humans, derived from a mold Penicillins with beta-lactamase inhibitors – Penicillium notatum • Amoxicillin – clavulanic acid (Augmentin).[1] • Nucleus – thiazolidine and beta-lactam rings to which side chains are attached through an amide MECHANISM OF ACTION linkage.[1] • Beta-lactam antibiotics – bactericidal, inhibits cell wall synthesis Classification of Penicillins • Inhibit transpeptidases – cross-linking does not take Natural penicillin place [2] • Penicillin G (benzyl penicillin) • Enzymes + related proteins – PBP. • Procaine penicillin G • Benzathine penicillin G. PREPARATION AND DOSAGE 1. PnG injection 0.5–5 MU IM or I.V 6–12 h – Dry pow- Acid-resistant penicillin der in vials to be dissolved in sterile water • Phenoxymethylpenicillin (penicillin V) 2.
    [Show full text]
  • Separation and Purification of Pharmaceuticals and Antibiotics [Table IX-1-1] Principal Antibiotics Penicillin-G (Benzylpenicillin), Oxacillin, Chlox- 1
    Separation and Purification of Pharmaceuticals and Antibiotics [Table IX-1-1] Principal Antibiotics Penicillin-G (benzylpenicillin), Oxacillin, Chlox- 1. Antibiotics acillin, Dichloxacillin, Nafcillin, Methicillin, (1) Outline Amoxicillin, Ampicillin, Ticarcillin, Piperacillin, Penicillins aspoxicillin, Antibiotics are "chemical substances produced by microorganisms Ciclacillin, Sulbenicillin, Talampicillin, which, in minute quantities, inhibit or suppress the proliferation of other Bacampicillin, Pivmecillinam, lenampicillin, microorganisms". This is defined in 1942 by Selman Abraham Waksman β-Lactams Phenethicillin, Carbenicillin etc, in the USA. Antibiotics were developed in Britain following the discovery Cephalosporin C of Penicillin in 1929 by Alexander Fleming: He found that Blue mold, Cefazolin, Cefatrizine, Cefadroxil, Cefalexin, Cephalosporins Cefaloglycin, Cefalothin, Cefaloridine, Cefoxitin, Penicillium, dissolves Staphylococcus staphylococci and inhibits its Cefotaxime, Cefoperazone, Ceftizoxime, Cefmet- growth and he named the extract from Penicillium as Penicillin. Many azole, Cefradine, Cefroxadine etc. new antibiotics have been found since 1940’s, and there are more than Other β-lactams 1,500 antibiotics. Principal ones are listed in Table IX-1-1. Kanamycins Amikacin, Kanamycin, Dibekacin Most of these antibiotics are manufactured by fermentation or by Gentamycins, Gentamicin, Micronomicin semi-synthesis that combines fermentation and organic synthesis, though Sisomycins chloramphenicol is by synthesis. Fermentation is carried out by Acti- Streptomycins Streptomycin Aminoglycosides nomycetes, mold (hyphomycetes) or bacteria in culture media with glu- Spectinomycins Spectinomycin cose, sucrose, lactose, starch or dextrin as carbon source, with nitrate, Fradiomycins Fradiomycin, ammonium salt, corn steep liquor, peptone, meat extract or yeast extract Astromicins Astromicin as nitrogen source and with a little amount of inorganic salts. Erythromycin, Oleandomycin, Carbomycin, Penicillin-type antibiotics are manufactured by semi-synthesis, i.e.
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]
  • Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
    WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) Critically Important Antimicrobials for Human Medicine 5th Revision 2016 Ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use Critically important antimicrobials for human medicine – 5th rev. ISBN 978-92-4-151222-0 © World Health Organization 2017, Updated in June 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/ igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Critically important antimicrobials for human medicine – 5th rev. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]